None
Conditions
Interventions
A:Anesthesia induction was initiated with sufentanil (Yichang Renfu Pharmaceutical, H20054171, 1 mL:50 µg), and maintenance was achieved with remifentanil (Yichang Renfu Pharmaceutical, H20030197, 1 m
B:Anesthesia induction was initiated with sufentanil (Yichang Renfu Pharmaceutical, H20054171, 1 mL:50 µg), and maintenance was achieved with remifentanil (Yichang Renfu Pharmaceutical, H20030197, 1 m
C:Anesthesia induction was initiated with sufentanil (Yichang Renfu Pharmaceutical, H20054171, 1 mL:50 µg), and maintenance was achieved with remifentanil (Yichang Renfu Pharmaceutical, H20030197, 1 m
Sponsors
Putian First Hospital
Eligibility
Sex/Gender
All
Age
50 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) No contraindications for spinal anesthesia or epidural anesthesia. (2) American Society of Anesthesiologists (ASA) classification I-II. (3) Informed and consenting participants for this study. (4) Middle-aged and elderly patients aged 50 years or above.
Exclusion criteria
Exclusion criteria: (1) Individuals with symptoms of depression or related mental disorders. (2) Individuals with allergies to relevant medications. (3) Individuals with a history of alcohol or substance dependence for more than six months. (4) History of abuse or dependence on ketamine. (5) Individuals with abnormal coagulation function, liver, or kidney dysfunction, or those with hypertension or diabetes. (6) Individuals with a failed epidural block.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| heart rate variability ;Hemodynamic parameters; | — |
Secondary
| Measure | Time frame |
|---|---|
| Anesthesia Safety;Cognitive function; | — |
Countries
China
Contacts
Public ContactShurong Li
Putian First Hospital
Outcome results
None listed